Digital PCR-based deep quantitative profiling delineates 1

heterogeneity and evolution of uveal melanoma 2

3	R.J. Nell ¹
4	M. Versluis ¹
5	N.V. Menger ¹
6	R.M. Verdijk ^{2,3}
7	W.G.M. Kroes ⁴
8	H.W. Kapiteijn⁵
9	G.P.M. Luyten ¹
10	M.J. Jager ¹
11	P.A. van der Velden ^{1*}
12	
13	¹ Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
14	² Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
15	³ Department of Pathology, Erasmus MC University Medical Center, Rotterdam, the
16	Netherlands.
17	⁴ Department of Clinical Genetics, Leiden University Medical Center, Leiden, the
18	Netherlands.
19	⁵ Department of Medical Oncology, Leiden University Medical Center, Leiden, the
20	Netherlands.
21	
22	* Corresponding author, Department of Ophthalmology, Leiden University Medical Center,
23	PO Box 9600, 2300 RC Leiden, The Netherlands
24	
25	
26	Acknowledgements
27	This study was supported by the European Union's Horizon 2020 research and innovation
28	program under grant agreement number 667787 (UM Cure 2020, R.J. Nell and N.V.
29	Menger). We thank D. Cats. H. Mei. L. van Vught and M.C. Gelmi for their help with the

30 sequencing data and clinical information from the patients in this study.

Abstract 31

- 32 Uveal melanoma is an aggressive intraocular tumour characterised by a limited number of
- 33 genetic alterations. However, the evolution of this malignancy remains enigmatic. In this
- 34 study, we performed a deep quantitative analysis of 80 primary uveal melanomas by novel
- digital PCR-based approaches. Mutations were quantified by targeted and drop-off mutation 35
- 36 assavs, copy number alterations were precisely measured by quantifying the allelic
- 37 imbalance of heterozygous single-nucleotide polymorphisms. By comparing the absolute
- 38 abundances of genetic alterations present in a bulk tumour, the heterogeneity and early
- 39 evolution could be inferred. Tumour progression was further studied by analysing matched
- 40 primary and metastatic lesions from five patients.
- 41

42 $G\alpha_{\alpha}$ signalling mutations were generically and always clonally present, suggesting to be 43 acquired in the earliest stage of uveal melanoma development ('primary driver'). Next, three 44 main evolutionary subtypes could be identified based on having an EIF1AX mutation, SF3B1 45 mutation or monosomy 3p. These alterations were usually mutually-exclusive and (near-) 46 clonally abundant, suggesting to represent distinct secondary drivers. This contrasts with 47 gains and amplifications of chromosome 8q, which were not restricted to one of the main 48 subtypes and showed subclonality in 31% of the affected tumours. These tertiary alterations 49 were not required for metastatic dissemination. 50

51 Using high-resolution analyses, we identified systematic differences in the evolutionary

- 52 timing of genetic events in uveal melanoma. The observed intratumour heterogeneity
- 53 suggests a more complex model of gradual tumour evolution and argues for a
- 54 comprehensive genetic analysis in clinical practice, which may be facilitated by the sensitive
- digital PCR assays developed in this study. 55

56 Introduction

57 Uveal melanoma (UM) is a rare, but often lethal tumour originating from malignantly

- transformed melanocytes in the choroid, ciliary body or iris in the eye [1, 2]. Unlike other
- 59 types of melanomas, UMs present with a limited mutational burden and low number of
- 60 structural variants [3, 4]. Nearly all tumours have a mutation in *GNAQ*, *GNA11*, *PLCB4* or
- 61 CYSLTR2, which activates the $G\alpha_q$ signalling pathway [5-8]. Most melanomas also harbour a
- 62 so-called BSE mutation in *BAP1*, *SF3B1* or *EIF1AX* [3, 9-11]. The loss of chromosome 3p
- 63 and the gain (i.e. one extra copy) or amplification (i.e. two or more extra copies) of
- 64 chromosome 8q are the most prevalent copy number alterations (CNAs), and occur in typical
- 65 combinations with the BSE mutations [12]. These distinct molecular subtypes are associated
- 66 with specific gene expression profiles and are differentially correlated with the risk of
- 67 metastatic spreading and patient survival [12-14].
- 68

69 Despite the large number of tumours studied, the evolution of UM remains incompletely

- 70 understood [15-17]. Based on comprehensive bioinformatic analyses, UM has been
- 71 proposed to arise after an early punctuated burst of the canonical genetic alterations, leading
- to relatively homogeneous tumours (i.e. most alterations are present in all malignant cells)
- 73 [15, 17]. However, as most genomic data on UM have been generated by DNA sequencing
- of low to moderate depths, and the number of mutations is minimal in most tumours, these
- 75 datasets may lack the power to reliably infer subclonal structures of heterogeneous tumours
- 76 (i.e. alterations are present in varying proportions of the malignant cells) [18]. Recent work
- studying UMs in higher resolution (i.e. analyses at the level of single cells or of distinct
- 78 progression stages) revealed a larger genomic complexity than appreciated previously [16,
- 19]. Though, these studies were carried out in relatively small cohorts or focussed
- 80 specifically on the evolution of metastatic tumours, leaving the early evolution of primary UM
- 81 relatively understudied. Moreover, as they were performed using advanced technical
- 82 approaches, routine application of these techniques remains unavailable in research or
- 83 clinical diagnostics.
- 84

As an alternative approach, a deep quantitative profiling of individual bulk DNA samples may provide insights into the heterogeneity and evolution of tumours, as we previously demonstrated in familial melanoma and *CYSLTR2* mutant UM [20, 21]. By determining the exact abundance of mutations and CNAs present in the bulk of a tumour, the inferred clonality of these alterations can be used to reconstruct the tumour's genetic history: those alterations that are present in all malignant cells ('clonal') occurred early during tumour

- 91 evolution, while events present in a subpopulation of the cells ('subclonal') occurred later
- 92 during progression of the tumour.
- 93
- 94 In this study, we perform such in-depth characterisation of 80 primary UMs and five matched
- 95 metastatic lesions using innovative digital PCR-based assays targeting the key genetic
- 96 alterations of this malignancy. Hereby, we aim to delineate the heterogeneity of tumours and
- 97 infer trends in the early and late evolution of UM.

98 Materials and methods

99 LUMC cohort sample collection and DNA/RNA isolation

100 Primary tumour specimens from 80 fresh-frozen UMs were collected from the biobank of the 101 Department of Ophthalmology, Leiden University Medical Center (LUMC). All samples were 102 obtained from patients primarily treated by enucleation between 2001 and 2011 in the 103 LUMC. In addition, we collected five formalin-fixed and paraffin embedded (FFPE) biopsy 104 specimens from tumour-matched metastatic lesions. This study was approved by the LUMC 105 Biobank Committee and Medisch Ethische Toetsingscommissie under no. B14.003/DH/sh 106 and B20.026. An overview of the clinical characteristics of all cases analysed in this study is 107 presented in Supplementary Table 1.

108

109 DNA and RNA were isolated from 25x 20 µm sections using the QIAamp DNA Mini Kit and

110 RNeasy Mini Kit respectively (Qiagen, Hilden, Germany). Total nucleic acid from FFPE

111 tissue was isolated 4x 10 µm macrodissected sections using the Siemens Tissue

112 Preparation System (Siemens Healthcare, Erlangen, Germany) [22]. For all procedures, the

- 113 manufacturer's instructions were followed.
- 114

115 **RNA sequencing analysis**

116 We sequenced and analysed 100 ng of RNA per primary tumour sample as described 117 previously [23]. In summary, samples were prepared using the NEBNext Ultra Directional 118 RNA Library Prep Kit for Illumina (New England Biolabs, Ipswich, USA) and sequencing was 119 performed using the Illumina HiSeg 4000 (Illumina, San Diego, USA) by GenomeScan 120 (Leiden, the Netherlands). HiSeg control and image analysis, base calling and quality check were carried out using HCS (version 3.4.0), the Illumina data analysis pipeline RTA (version 121 122 2.7.7) and Bcl2fastg (version 2.17). Reads were aligned using STAR (version 2.5.3a) to 123 human reference genome GRCh38. Gene counts were generated with htseg-count (version 124 0.6.0) and annotated using Ensembl (version 87). DESeq2 (version 1.30.0) was used for 125 variance stabilising transformation of the count data. All aligned RNA sequencing files were 126 screened for (hotspot) mutations in GNAQ (p.Q209, p.R183 and p.G48), GNA11 (p.Q209, 127 p.R183), CYSLTR2 (p.L129), PLCB4 (p.D630), EIF1AX (entire gene), SF3B1 (exon 14) and 128 BAP1 (entire gene) using freebayes (version 1.3.6), and via manual inspection using the Integrative Genomics Viewer (version 2.8.10). The aligned RNA sequencing files were 129 130 further analysed for single-nucleotide polymorphisms (SNPs) using VarScan (version 2.3), 131 which were annotated using snpEff/snpSift (version 5.1) according to dbSNP (version 151). 132 Only heterozygously and highly expressed common variants (flagged as 'common', total

- 133 number of reads > 40, number of reference reads > 2, number of alternate reads > 2) were
- 134 included in the downstream analysis to identify CNA-derived allelic imbalances.
- 135

136 Digital PCR experiments and integration of results

- 137 Digital PCR experiments were carried out using the QX200 Droplet Digital PCR System (Bio-
- 138 Rad Laboratories, Hercules, USA) following the protocols and general guidelines described
- and discussed earlier [21, 24-27]. In general, 20 ng DNA was analysed in a 22 uL
- 140 experiment, using 11 uL ddPCR™ Supermix for Probes (No dUTP, Bio-Rad) and primers
- 141 and probes in final concentrations of 900 and 250 nM for duplex experiments, or optimised
- 142 concentrations for multiplex experiments. The context sequence, PCR annealing
- 143 temperature and supplier information for all assays used is provided in **Supplementary**
- 144 **Table 2**.
- 145
- 146 PCR mixtures were partitioned into 20.000 droplets using the AutoDG System (Bio-Rad).
- 147 The PCR was performed in a T100 Thermal Cycler (Bio-Rad) with the following protocol: 10
- 148 min at 95 °C; 30 s at 94 °C and 1 min at 55 °C, 58 °C or 60 °C (depending on the assay, see 149 **Supplementary Table 2**) for 40 cycles; 10 min at 98 °C; cooling at 12 °C for up to 48 h, until
- droplet reading. The ramp rate was set to 2 °C/s for all steps. A QX200 Droplet Reader (BioRad) was used to perform reading of the droplets.
- 152

153 Raw digital PCR results were acquired using QuantaSoft (version 1.7.4, Bio-Rad) and

- 154 imported and analysed in the online digital PCR management and analysis application
- 155 Roodcom WebAnalysis (version 2.0, available via <u>https://webanalysis.roodcom.nl</u>).
- 156
- 157 The Gα_q signalling mutations (in *GNAQ*, *GNA11*, *CYSLTR2* and *PLCB4*) and BSE mutations
- 158 (in *BAP1*, *SF3B1* and *EIF1AX*) were analysed in duplex digital PCR experiments and the
- 159 measured concentrations (listed between square brackets) of the mutant and wild-type
- 160 alleles were used to calculate the mutant allele fractions:
- 161
- 162 mutant allele fraction = [mutation] [mutation] + [wildtype]
 163
 164 These values were then used to estimate the mutant cell fractions under heterozygous
 165 conditions:
- 166
- 167 mutant cell fraction = 2 · mutant allele fraction

168	
169	In line with our recent study [27], two approaches were employed to measure CNAs. Firstly,
170	following the classic approach, copy number values were calculated based on the measured
171	concentrations of a DNA target and one stable diploid reference gene:
172	
173	$copy number value = 2 \cdot \frac{[target]}{1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 +$
474	[reference]
174	The targets included genes on chromosome 3n (PRAPC) and 8g (PTK2). Cones on
176	chromosome 5n (TERT) 7n (VOPP1) 7n (BRAE) or 14n (TTC5) were evaluated as stable
177	references. Moreover, we used this approach to evaluate the copy number values of the
178	mutant and wild-type alleles in the case of an allelic imbalance affecting the $G\alpha_{a}$ signalling
179	and BSE genes. As described earlier [21] these additional measurements allowed to
180	calculate the mutant cell fractions under non-heterozygous conditions:
181	
	[mutation]
182	mutant cell fraction (with loss or gain of wild-type allele) = $2 \cdot \frac{1}{[reference]}$
183	= copy number value · mutant allele fraction
184	
185	mutant cell fraction (with gain of mutant allele) = 2 - 2 · [wildtype] [reference]
186	= 2 - copy number value · (1 - mutant allele fraction)
187	
188	Secondly, following the SNP-based approach, copy number values were measured using
189	the concentrations of haploid genomic loci var $_1$ and var $_2$, representing the two variants of a
190	heterozygous SNP:
191	
192	copy number value = 1 + [var ₁] [var ₂]
193	
194	In this formula, the SNP variant in the denominator (var_2) is the one assumed to be unaltered
195	and copy number stable (i.e. haploid). When measuring (potential) chromosomal losses, the
196	variant with the highest concentration was chosen as stable variant. Vice versa, the variant
197	with the lowest concentration was assumed to be stable when analysing chromosomal gains
198	and amplifications. Analysed SNPs in this study included rs6617, rs6976, rs9586,
199	rs1989839, rs1062633 and rs2236947 on chromosome 3p, and rs7018178 and rs7843014
200	on chromosome 8q.

201 202 The clonality of the genetic alterations was primarily assessed by comparing the mutant cell 203 fractions in individual tumours. In most samples, the $G\alpha_{a}$ signalling mutation represented the 204 largest and thus clonal fraction of cancer cells and was considered an accurate estimate of 205 the total fraction malignant cells (i.e. tumour purity). The clonality of CNAs was determined 206 by adjusting the measured copy number values for this tumour purity (assuming that 207 admixed non-malignant cells always have a copy number value of 2). Non-integral outcomes were considered subclonal. For simple CNAs (between -1 and +1), the quantified loss or 208 209 gain can be mathematically attributed to a specific proportion of the cells in a tumour [21]: 210 211 cell fraction with copy number loss = (2 - copy number value)212 213 cell fraction with copy number gain = (copy number value - 2)214 215 For all digital PCR experiments, 99%-confidence intervals were calculated following Fieller's 216 theorem and taken into account in all calculations [28]. P values < 0.01 were considered 217 statistically significant. 218 219 Validation of findings with karyotyping and BAP1 immunohistochemistry 220 In a selection of cases, the heterogeneity of CNAs and presence and pathogenicity of BAP1 221 alterations were confirmed by karyotyping and an immunohistochemical staining, both 222 performed as routine diagnostic analyses in two ISO accredited laboratories (Departments of 223 Pathology, LUMC) [25, 29, 30]. 224 225 **Bioinformatic analyses and data availability** 226 The bioinformatic analyses were carried out using R (version 4.0.3) and RStudio (version 227 1.4.1103). Custom scripts and unprocessed results are available via 228 https://github.com/rjnell/um-heterogeneity. The molecular interpretation of all cases analysed

in this study is presented in **Supplementary Table 1**.

230 **Results**

231 Sample collection and RNA sequencing analysis

Primary UM specimens from 80 patients were studied for mutations and CNAs at the DNA
level using digital PCR. As this is a largely targeted technique, RNA sequencing was
performed to screen for the presence of genetic alterations, an approach we recently
validated for UM [23]. In addition, RNA sequencing was used to divide our cohort into class I
(n=29) or class II (n=51) tumours, based on their bulk gene expression profile (GEP). An
overview of the molecular and clinical characteristics of all cases is presented in Figure 1
and Supplementary Table 1.

239

240 $G\alpha_q$ and BSE mutation analysis

Gα_q signalling mutations were detected in 79/80 (99%) tumours of the LUMC cohort and
analysed at the DNA level via accustomed targeted digital PCR assays (Figure 2A and
Supplementary Table 1) Although the mutations recurrently affected the established
hotspot positions (p.Q209 and p.R183 in *GNAQ/GNA11*, p.D630 in *PLCB4* and p.L129 in *CYSLTR2*), considerable variation was present at the nucleotide level (Figure 2B). The *GNAQ* p.G48L mutation, which seems to represent a rare alternative hotspot [12, 16, 31,
32], was identified in one tumour.

248

249 EIF1AX mutations are known to affect the two first exons of the gene [11], and were 250 detected using RNA sequencing in 11/80 (14%) cases (Figure 3A and Supplementary 251 **Table 1**). To verify these mutations at the DNA level, we developed two drop-off digital PCR 252 assays. These assays were designed to target a polymorphic wild-type sequence using two fluorophore-labelled probes within one PCR amplicon [33]. When wild-type alleles are 253 254 present, a double-positive signal is measured, while when a mutation is present, one of the 255 two probes 'drops off' and single-positive droplets appear (Figure 3B). This way, we were 256 able to confirm and quantify the presence of all 11 mutations using only two generic assays. 257

- SF3B1 (Splicing Factor 3B subunit 1A) encodes for a component of the splicing machinery
 and mutations in this gene result in aberrant splicing [3, 34]. Focussing on the exon 14
 hotspot region, RNA sequencing identified SF3B1 mutations in 18/80 (23%) melanomas,
- with 14 cases affecting the p.R625 position (**Figure 3A and Supplementary Table 1**).
- 262 SF3B1-mutation-associated deregulated splicing was observed in 17/18 mutant cases, while
- this was not detected in any of the *SF3B1*-wild-type tumours (**Figure 3C**). The only
- discordant case (LUMC-79) harboured a novel *SF3B1* p.A638S mutation of unknown

pathogenic significance. The *SF3B1* mutant allele fractions were quantified at the DNA level
in 16 cases using digital PCR assays targeting the p.R625C or p.R625H mutation and a
dedicated drop-off assay.

268

269 Inactivating BAP1 mutations (or deletions) can be found throughout the complete BAP1 270 gene, challenging the identification of all of these alterations using conventional sequencing 271 [15, 35]. RNA sequencing of our cohort helped us to identify 43/80 (55%) tumours with various types of probably damaging BAP1 alterations (Figure 3A and Supplementary 272 273 **Table 1**). In five tumours, the sequencing reads insufficiently covered the entire gene, and 274 no conclusions could be drawn on the presence of any mutation. For a selection of cases, an 275 immunohistochemical BAP1 protein staining confirmed the presence or absence of BAP1 276 inactivating alterations (Figure 3D and Supplementary Table 1). To analyse the exact 277 abundance and clonality of a variety of BAP1 mutations, we developed one drop-off and

- eight targeted digital PCR assays by which 15 tumours from our cohort could be
- 279 characterised.
- 280

281 Allele-specific copy number analysis of chromosome 3p and 8q alterations

Extending our recent proof-of-concept study [27], chromosome 3p and 8q CNAs were
analysed using two complementary digital PCR-based approaches. For the classic
approach, targets on chromosome 3p and 8q were quantified against a stable reference
gene using multiplex digital PCR. As a reference-independent alternative, CNA-derived
allelic imbalances were measured by quantifying the two variants of heterozygous common
SNPs on chromosome 3p and 8q in duplex digital PCR experiments.

288

289 Generally, both approaches resulted in highly comparable copy number values (Spearman's 290 rho = 0.95, p < 0.001, Figure 4A). By integrating the values determined with the classic and 291 SNP-based approaches, copy number stability of one allele (i.e. one SNP variant) could be 292 assured in most tumours (Figure 4B). This confirms our earlier observation that CNAs 293 affecting chromosomes 3p and 8g usually involve only one of both alleles [27]. In our current 294 cohort, we did not identify cases with isodisomy 3p, which would have been visible as a 295 large allelic imbalance in combination with an absent or limited absolute loss of chromosome 296 3p. Moreover, in 49/55 (89%) of the informative tumours, the chromosome 8g copy number 297 value could be correctly estimated based on the allelic (im)balance, which required genomic 298 stability of at least one of both alleles (i.e. one SNP variant). This indicates that 8q copy 299 number increases, including the larger amplifications, are predominantly derived from the 300 (consecutive) gain of the maternal or paternal allele solely (Figure 4B). In six tumours we

301 observed that the amplification originated from gaining both alleles. Since the allele-specific

- 302 copy numbers were significantly different in all these cases (**Supplementary Figure 1A**),
- 303 these amplifications are likely the result of separate genetic events. As representatively
- 304 illustrated by case LUMC-75, for which we integrated our copy number data with the allelic
- imbalances observed in the RNA sequencing data [23], a multi-chromosomal or genome-
- 306 wide ploidy change could be excluded, indicating that the amplification was acquired via an
- 307 8q-specific mechanism (**Supplementary Figure 1B**). In 31 tumours, chromosome 3p and/or
- 308 8q copy numbers could be determined via multiple heterozygous SNPs, which further
- 309 validated the technical reproducibility of our assays and SNP-based approach
- 310 (Supplementary Figure 1C). As this approach in line with our recent study [27] also led
- 311 to more precise copy number measurements (**Supplementary Figure 1D**), we focussed on
- the SNP-based results in downstream evaluation of all copy numbers.
- 313

314 Clonality analysis integrating mutations and CNAs

315 By comparing the absolute abundances of the somatic genetic alterations present in a bulk 316 tumour, the clonality and heterogeneity of individual cases can be inferred [36-39]. For this 317 goal, we integrated the quantified mutant allele fractions with the copy number states of the 318 respective genomic loci (indicating zygosity of the mutations, see **Methods**) to determine the 319 $G\alpha_{\alpha}$, *EIF1AX*, *SF3B1* and *BAP1* mutant cell fractions (**Figure 5A**). Through adjusting all 320 copy number values for tumour purity (i.e. the fraction malignant cancer cells in a tumour 321 sample), the clonality of the various CNAs could also be assessed (Figure 5A). This 322 analysis was based on the assumption that CNAs – when clonally present in all malignant 323 cells – should give an integral copy number: -1 for a loss, +1 for a gain and +2, +3, +4 et 324 cetera for an amplification. When the copy number is significantly different from these 325 integral values, the alteration can only originate from a mixture of subpopulations, as 326 exemplified by comparing our bulk measurements to single-cell karyotyping (Figure 5B, 327 complete karyograms are presented in **Supplementary Figure 2**). For simple CNAs 328 (between -1 and +1), the quantified loss or gain can be mathematically attributed to a 329 certain proportion of the tumour cells.

330

A total of 79/80 primary UMs of our cohort carried a $G\alpha_q$ signalling mutation, which was always clonally expanded (**Figure 5C-D**). Although the $G\alpha_q$ mutations were typically heterozygous, in 8/79 (10%) tumours an additional CNA altered the absolute or relative dosage of the mutant allele. This involved loss of wild-type *GNAQ* (n=3), loss of wild-type

335 GNA11 (n=1), gain of mutant GNAQ (n=1) and gain of wild-type GNAQ (n=1), next to the

- cases with loss of wild-type CYSLTR2 (n=1) and gain of mutant CYSLTR2 (n=1) described
 previously [21]. These additional alterations were subclonal in 6/8 tumours (Figure 5E).
- 339 Mutations in *EIF1AX* were found in 10 melanomas and were clonally present in the entire
- population of malignant cells in nearly all cases (Figure 5C). Only one tumour showed a
- small but significantly detectable fraction of $G\alpha_q$ mutant malignant cells that were *EIF1AX*
- 342 wild-type (p < 0.01, **Figure 5D**). As *EIF1AX* is located on chromosome X, differences were
- 343 observed in the abundances of mutant and wild-type alleles between female (n=1,
- heterozygous mutation) and male patients (n=10, hemizygous mutation), but in none of the
- tumours additional CNAs involving this gene were identified.
- 346

347 *SF3B1* mutations were found in 18 tumours, of which 16 could be further analysed and also 348 tended to be clonally present (**Figure 5C**). In only one case a small fraction of *SF3B1* wild-349 type malignant cells (p < 0.01, **Figure 5D**) was measured. No CNAs affecting mutant or wild-350 type *SF3B1* were identified.

351

Loss of chromosome 3p was observed in 52/80 (65%) of the tumours. This monosomy was clonally expanded in most tumours (**Figure 5C**). Two GEP class II tumours presented with a small fraction of disomic malignant cells, of which one was *CYSLTR2* mutant and described in our earlier study [21]. Of the GEP class I tumours, only one showed monosomy, which turned out to be subclonally present in a larger fraction of the malignant cells (p < 0.01,

- 357 **Figure 5D**).
- 358

Pathogenic *BAP1* alterations were detected in 46 tumours (all presenting with monosomy 3p) and targeted analysis in a selection of 15 tumours confirmed a clonal inactivation of *BAP1* in 14 cases: both the mutation and the loss of the other chromosome 3p were present in the complete $G\alpha_q$ mutant malignant cell fraction (**Figure 5C**). In one tumour, we observed that the *BAP1* mutation was only present in a subclone (p < 0.01), while the monosomy 3p was clonally present in all malignant cells (**Figure 5D**).

365

366 Only 15/80 (19%) tumours of our cohort had a normal copy number of chromosome 8q. In 367 those tumours with a detected gain or amplification, large variation was observed in the 368 absolute numbers of additional copies (**Figure 5A**). In total, subclonal gains were found in 13 369 tumours, clonal gains in 17 tumours, subclonal amplifications in 12 tumours and clonal 370 amplifications in 23 tumours.

- 371
- 372

373 Identification of three main UM subtypes based on clonality and mutual-exclusivity

- 374 Taken together, a single clonal $G\alpha_{a}$ signalling mutation was found in nearly all studied
- tumours, making it the most generic genetic event in our cohort. Though, most UMs acquired
- additional alterations (**Figure 5A**). Based on trends in their clonality and mutual-exclusivity,
- three main subgroups of tumours could be defined by (1) a disomy 3p with an *EIF1AX*
- 378 mutation (8/80, 10% of our cohort), (2) a disomy 3p with an *SF3B1* mutation (14/80, 18%), or
- (3) a monosomy 3p (47/80, 59%). As these genetic alterations were all (near-)clonally
- abundant, it is likely that they occurred early during UM development.
- 381
- 382 In contrast, chromosome 8q CNAs were not restricted to one of these three subtypes nor
- 383 obligately present in all tumours of one subtype. Moreover, these copy number increases
- frequently showed subclonality (**Figure 5A**). This indicates that in contrast to the clonal
- alterations 8q copy number increases were only present in subpopulations of the
- 386 malignant cells and were acquired at a later evolutionary time point.
- 387
- 388 When the loss of chromosome 3p is accompanied by a mutation in *BAP1*, a complete
- inactivation of this tumour suppressor gene can be accomplished. Similar to the
- 390 heterogeneity of chromosome 8q CNAs *BAP1* alterations were not detected in all
- 391 monosomic tumours of our cohort, BAP1 protein expression was not always lost and the
- 392 *BAP1* mutation was not always clonally expanded (**Figure 3D and 5A**).
- 393
- The remaining cases (11/80, 14%) were collectively grouped for their 'alternative' profile of genetic alterations with none (n=1) or two clonal $G\alpha_q$ mutations (n=1), a disomy 3p without any detectable BSE mutation (n=5) or with both a clonal *EIF1AX* and *SF3B1* mutation (n=1), a clonal monosomy 3p with both a clonal *BAP1* and *EIF1AX* mutation (n=1) or a clonal *BAP1* and *SF3B1* mutation (n=1), or a clonal *SF3B1* mutation with a subclonal monosomy 3p (n=1). In these tumours chromosome 8q gains and amplifications were also heterogeneously
- 400 present.
- 401

Of note, the inferred tumour purity differed substantially between individual tumours (median
86%, range 25-100%), with the lowest fractions of malignant cells observed in UMs with loss
of chromosome 3p (Figure 5A and Supplementary Table 1).

405

From a clinical perspective, univariate analyses showed that a larger basal diameter, a lack
of *SF3B1* mutation, a loss of chromosome 3p and a higher 8q copy number were related to a
worse melanoma-related survival (**Table 1**). Age, gender, tumour prominence and having an

- 409 *EIF1AX* mutation did not reach statistical significance. In a multivariate analysis, only the
- 410 largest basal diameter of the tumour and the loss of chromosome 3p remained significantly
- 411 associated with a poor melanoma-related survival.
- 412

413 Analysis of five metastases reveals parallel 8q evolution

414 To investigate the clonality and heterogeneity of the primary UMs in relation to metastatic

- 415 progression, we extended our study with the genetic analysis of metastatic lesions from five416 patients of our cohort.
- 417

418 Several genetic alterations were shared between the primary tumours and matched

419 metastases (**Figure 6A**). This included $G\alpha_q$ signalling mutations in all patients, SF3B1

420 mutations in LUMC-42 and -22, chromosome 3p losses in LUMC-29, -79 and -73, and BAP1

421 mutations in LUMC-79 and -73. All these alterations were clonally abundant in both primary

tumour and metastasis, suggesting to reside on the trunk of the evolutionary trees (**Figure**

423

6B).

424

425 Regarding chromosome 8q, however, large variation was observed between the primary and 426 metastatic lesions (Figure 6A). In LUMC-29 and -73 no chromosome 8q copy number 427 increases were detected in the primary tumours, but the metastases presented with a 428 subclonal gain or clonal amplification of this chromosome. In LUMC-42 the primary tumour 429 had a clonal 8q gain, but the metastasis presented with a disomy 8q. In LUMC-22 and -79 a 430 subclonal 8q gain was identified in the primary tumour, but the metastatic lesions harboured 431 a subclonal gain and clonal amplification of the other allele of chromosome 8g (Figure 6A 432 and B).

433

In aggregate, 8q copy number increases encompassed independent evolutionary events that could be placed on separate branches of the evolutionary trees (**Figure 6C**). In all patients, the metastatic clone was most likely derived from primary tumour cells carrying a panel of genetic alterations ($G\alpha_q$ signalling mutation, *SF3B1* mutation, chromosome 3p loss and/or *BAP1* mutation), but a disomy 8q. Additional 8q copies were acquired later, during progression of primary tumour or metastasis (**Figure 6C**).

440 **Discussion**

441 Cancer develops through the accumulation of somatic genetic alterations over time [40, 41]. 442 The evolution of human malignancies, including various forms of melanoma, has been 443 elucidated by comparing the genetic make-up of distinct progression stages of individual 444 tumours [42-45]. In UM, however, tumour material is only scarcely available and 445 histologically distinct precursor lesions next to a melanoma are rarely observed [1]. 446 Consequently, the (early) evolution of this malignancy remains incompletely understood [15-447 17]. As an alternative approach, the evolutionary history of an individual tumour can be 448 inferred by a deep quantitative assessment of the genetic alterations present in the bulk of a 449 single tumour biopsy [36-39]. To better understand the development of UM, we performed 450 such in-depth analysis by focussing on the most common mutations and CNAs in this 451 malignancy. For this goal, we successfully screened RNA sequencing data from 80 primary 452 UMs for their genetic alterations, and effectively applied novel, dedicated digital PCR assays 453 to measure the clonality of these alterations at the DNA level. 454 455 In 99% of the tumours in our cohort, we identified an activating $G\alpha_{\alpha}$ signalling mutation in 456 GNAQ, GNA11, CYSLTR2 or PLCB4, confirming their ubiquitous presence in UM (Figure 457 1). We found (almost completely) mutually-exclusive mutations at all established hotspots, including the rare GNAQ p.G48 position (Figure 2B). As the $G\alpha_q$ signalling mutations were 458 459 always clonally present, they were likely acquired in one of the earliest stages of tumour

460 development. The common presence of the same mutations in benign nevi and melanocytosis in the eye – both supposed precursors for UM – supports this hypothesis [21, 461 462 46, 47]. Consequently, a role in tumour initiation ('primary driver') rather than in malignant 463 progression is postulated. Several studies, nevertheless, guestion the relation between 464 mutations and activity of the $G\alpha_{\alpha}$ signalling genes and progression of UM [12, 48]. Additional 465 genetic alterations have been described that elevated the allelic balance at the mutant locus 466 towards the GNAQ or CYSLTR2 mutations [16, 21]. We identified such alterations in 9% of 467 the tumours in our cohort, and also one involving GNA11. Their typical presence in only a 468 tumour subclone confirms that these alterations were acquired in a later phase, during 469 progression of the primary tumour.

470

In addition to the early $G\alpha_q$ signalling mutation, most UMs acquired additional genetic

472 changes. These occurred in typical combinations and followed a recurring order of events,

473 as summarised in **Figure 7A**. Three main evolutionary UM subtypes could be identified

474 based on having an *EIF1AX* mutation, *SF3B1* mutation or monosomy 3p. These three

alterations were usually mutually-exclusive and clonally abundant, suggesting to represent

476 distinct 'secondary drivers'. This finding matches with the paradigm that tumours with an 477 EIF1AX mutation, SF3B1 mutation or monosomy 3p represent distinct molecular entities and 478 is in line with earlier reports of the EIF1AX and SF3B1 mutations typically being clonally 479 abundant [12, 15-17, 19]. However, in contrast to some previous studies [49, 50], we only 480 rarely observed heterogeneity of monosomy 3p within the malignant cell population. We 481 hypothesise that the low tumour purity of this latter subtype, sometimes even lower than 482 50% (Figure 5A), might explain why disomic and monosomic cells have frequently been found together. 483

484

In contrast, a complete and fully clonal inactivation of BAP1 was not found in all tumours with
monosomy 3p. This confirms occasional observations in earlier studies [12, 15, 16], and
suggests that a somatic mutation in this gene should also be seen as a later evolutionary
event. However, as complex *BAP1* alterations can be found throughout the entire gene
(**Figure 3A**), not all mutations were quantitatively measured using digital PCR and their
clonality could only be analysed in a small subset of the tumours.

491

492 We also found that gains and amplifications of chromosome 8g were not restricted to one of 493 the three UM subtypes and frequently showed subclonality. This strongly indicates that these 494 alterations could be seen as a 'tertiary driver'. Intriguingly, the role and evolutionary timing of 495 chromosome 8q increases has remained largely unclear and controversial until now [15-17, 496 25]. Using purity-corrected digital PCR-based quantifications, we generated copy number 497 measurements of much higher precision than previous studies. Although some tumours 498 demonstrated an apparently clonal gain or amplification, at least 31% of our cohort 499 presented with a mixture of cells with different 8q copy numbers, making it the most common 500 heterogeneous genetic alteration in primary UM. We confirmed the presence of this 501 heterogeneity in a number of cases using single-cell karyotyping and by analysing a 502 selection of tumour-matched metastatic lesions. These findings suggest a much more 503 complex role for chromosome 8g in UM biology than acknowledged previously. 504

505 The progressive ramp-up of 8q copy numbers has been reported as one of the most 506 significant genetic changes observed in the evolution from primary UM to metastasis [16]. 507 Our results, first of all, suggest that the acquisition of additional 8g copies is an ongoing 508 process during progression of the primary tumour: after the primary and secondary drivers 509 have clonally expanded, subclones with increasing 8g copy numbers may appear. Of note, 510 this increase is usually allele-specific, as it typically solely involves the (consecutive) gain of 511 the maternal or paternal allele. Though, it is not entirely clear how this 8q increase in the 512 primary tumour relates to the metastatic progression of UM. Higher 8g copy numbers have

513 been repetitively associated with a higher frequency of and a shorter time to the 514 development of metastatic disease [12, 24, 51-53]. These associations hold true in our 515 current cohort of tumours and may indicate that melanoma cells with higher 8g levels 516 metastasise more easily. On the other hand, UMs are typically large once detected, 517 suggesting a relatively long time of tumour evolution before the primary lesion is treated (and 518 analysed). The increasing 8g copy numbers might then be seen as a 'molecular clock' of 519 primary tumour progression, while not necessarily influencing the metastatic potential of the 520 individual cancer cells. In line with this hypothesis, all five metastatic lesions we analysed 521 were supposedly disseminated from a primary tumour clone with disomy 8g. Though, 8g 522 gains or amplifications were present in three of the primary tumours and four of the 523 metastatic lesions, but their allele-specificity and subclonality evidenced that these copy 524 number increases were separate genetic events, occurring independently in the late 525 evolution of both primary and metastatic UM (Figure 7B).

526

527 Taken together, but in contrast to earlier studies [15, 17], our findings point toward a model 528 of gradual evolution (**Figure 7**) in which a primary driver (i.e. a $G\alpha_{\alpha}$ signalling mutation) 529 initiates pre-malignant transformation, but a secondary driver (i.e. a mutation in EIF1AX, in 530 SF3B1, or the loss of chromosome 3p) is required for complete malignant UM development. 531 Subsequently, recurrent tertiary drivers (i.e. most notably chromosome 8q copy number 532 increases) may contribute to full aggressiveness of the cancer, but are not necessary for 533 metastatic dissemination and frequently show heterogeneity within and between tumour 534 lesions in a UM patient.

535

536 From a clinical perspective, the presence of any heterogeneity would necessitate a 537 comprehensive and detailed analysis when relying on the detection of genetic alterations in 538 determining the prognosis or follow-up of patients. This specifically applies to the exact (and 539 thus purity-corrected) measurement of the 8q copy number, as this number is a vital 540 parameter in an established classification system of primary UMs [51, 53, 54]. We propose 541 that the digital PCR assays introduced in this study may be an accessible solution to 542 facilitate this analysis. Additionally, our mutation and copy number assays have potential 543 application in sensitively measuring genetic UM patient material of lower quantity or quality, such as small solid or liquid biopsies. This is illustrated by the successful analysis of FFPE-544 derived metastases in this study. As another example, some of the mutation assays have 545 546 already been used in blood-based screening for circulating tumour DNA [55], and the clinical 547 value of similar applications is increasingly recognised [56].

- 549 Critically, our current study is limited by the sole analysis of primary tumours obtained from
- 550 enucleated eyes, making our cohort being biased toward larger and possibly more evolved
- 551 (and more clonal) tumours. We hypothesise that the earliest stages of tumour evolution may
- be studied by comparable in-depth analyses of smaller UMs. In addition, it would be
- 553 interesting to investigate more pairs of primary and metastatic UMs to better define the later
- 554 stages of UM evolution. Our evaluations may be further extended to the analysis of other
- 555 recurrent or sample-specific genetic alterations present in UM.
- 556
- 557 In conclusion, using novel digital PCR-based approaches, we identified systematic
- 558 differences in the evolutionary timing of the key genetic events in UM. The observed
- 559 intratumour heterogeneity suggests a more complex model of gradual tumour evolution and
- argues for a comprehensive genetic analysis in clinical practice, which may be facilitated by
- the sensitive digital PCR assays developed in this study.

562 Table

563 Table 1

Variable	Univ	ariate	Multivariate	
Variable	HR	<i>p</i> value	HR	<i>p</i> value
Age	1.001	0.941	0.988	0.397
Gender (male versus female)	0.855	0.652	1.160	0.680
Tumour prominence (mm)	1.019	0.744	0.979	0.742
Tumour largest basal diameter (mm)	1.143	<u>0.022</u>	1.149	<u>0.042</u>
EIF1AX mutation (versus wildtype)	0.185	0.096	0.474	0.526
SF3B1 mutation (versus wildtype)	0.324	<u>0.035</u>	0.670	0.607
Chromosome 3p loss (versus disomy)	5.667	<u><0.001</u>	4.325	<u>0.040</u>
Chromosome 8q (purity-corrected copy number)	1.397	<u>0.002</u>	0.968	0.840

564

565 Uni- and multivariate Cox proportional hazards analysis for factors associated with

566 melanoma-related survival. HR = hazard ratio, vs. = versus, bold underlined *p* values are

567 considered statistically significant (p < 0.05).

569 Figures

570 Figure 1



- 573 Overview of the GEP classification, clinical characteristics and genetic alterations in our
- 574 LUMC cohort of primary UMs.
- 575
- 576
- 010

Figure 2 577

A Targeted mutation digital PCR assay	WE 5000	В	GNAQ	p.Q209L p.Q209P p.G48L	c.A626T c.A626C c.GG142_143TT	n = 6 n = 27 n = 1
e.g. <i>GNA11</i> → p.Q209L	Channel 2500	». 	GNA11	p.Q209L p.Q209P p.R183Y p.R183H p.R183C	c.A626T c.CA625_626TT c.A626C c.CG547_548TA c.G548A c.C547T	n = 36 n = 1 n = 1 n = 2 n = 1 n = 1
mutant (FAM)wild-type (HEX)	0 250 Channe	0 5000 el 2 (HEX)	PLCB4 CYSLTR2	p.D630F p.D630N p.L129Q	c.GA1888_1889TT c.G1888A c.T386A	n = 1 n = 1 n = 2

- 580 (A) Analysis of hotspot $G\alpha_q$ signalling mutations using duplex digital PCR with FAM- and
- 581 HEX-labelled probes targeting the mutant and wild-type sequences.
- 582 (B) Prevalence and exact nucleotide variation of the $G\alpha_q$ signalling mutations in the LUMC
- 583 cohort.

584 Figure 3



- 587 (A) Lollipop plots demonstrating the distribution and prevalence of mutations in *EIF1AX*,
- 588 *SF3B1* and *BAP1* in the LUMC cohort. The colors refer the digital PCR assays available to
- analyse these mutations. Red and green boxes refer to selected gene domains.
- 590 (**B**) Illustration of the principle behind the digital PCR drop-off assays with two 2D plots as
- 591 examples of the *EIF1AX* exon 2 drop-off analysis.
- 592 (C) Analysis of a signature of alternative splicing to identify *SF3B1* mutant tumours.
- 593 (D) Representative immunohistochemical BAP1 nuclear stainings demonstrating preserved
- staining in *BAP1* wild-type tumours and lost staining in tumours with a *BAP1* mutation.

596 Figure 4



597

allele I allele II

598 (A) Comparison of chromosome 3p and 8q copy number values determined with the classic

599 and SNP-based approaches.

600 (B) Examples of integrated copy number values determined with both approaches, revealing

601 the allele-specificity behind the various alterations.

602 Figure 5



- 604 (A) Overview of presence, clonality and mutual-exclusivity of the various genetic alterations
- in the LUMC cohort. Additionally, the measured tumour purities and purity-corrected
- 606 chromosome 8q copy number values are presented
- 607 (**B**) Evidence of chromosome 8q heterogeneity by single-cell karyotyping.
- 608 (C) Examples of tumours with multiple clonal genetic alterations.
- 609 (**D**) Examples of tumours with a clonal $G\alpha_q$ signalling mutation and additional (sub)clonal
- 610 alterations. N/c: not calculable.

All rights reserved. No reuse allowed without permission.

611 Figure 6



612 613

614 (A) Overview of genetic alterations and their clonality in five pairs of primary tumours and

- 615 metastatic lesions. Additionally, the allele-specificity of the chromosome 8g CNAs is
- 616 presented.

(B) Extended from A. Detailed example of the clonality analysis in the samples from case 617

618 LUMC-22. Note that the chromosome 8q gain is subclonally present in both samples, but

- 619 involves a different allele.
- 620 (C) Inferred evolutionary trees of the uveal melanomas from the five patients.
- 621

622 Figure 7



- 624 (A) Main evolutionary subtypes of UMs with specified primary, secondary and additional
- 625 genetic alterations driving this evolution.
- 626 (**B**) Proposed model of gradual tumour evolution ultimately leading to heterogeneous primary
- 627 and metastatic UMs.

All rights reserved. No reuse allowed without permission.

628 **References**

- 629 1. Coupland, S.E., et al., *Molecular pathology of uveal melanoma*. Eye (Lond), 2013. 27(2): p. 230-42.
- 631 2. Jager, M.J., et al., Uveal melanoma. Nat Rev Dis Primers, 2020. 6(1): p. 24.
- 6323.Furney, S.J., et al., SF3B1 mutations are associated with alternative splicing in uveal633melanoma. Cancer Discov, 2013. **3**(10): p. 1122-1129.
- 634 4. Royer-Bertrand, B., et al., *Comprehensive Genetic Landscape of Uveal Melanoma by Whole-*635 *Genome Sequencing.* Am J Hum Genet, 2016. **99**(5): p. 1190-1198.
- 5. Van Raamsdonk, C.D., et al., *Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.* Nature, 2009. **457**(7229): p. 599-602.
- 638 6. Van Raamsdonk, C.D., et al., *Mutations in GNA11 in uveal melanoma.* N Engl J Med, 2010.
 363(23): p. 2191-9.
- Johansson, P., et al., *Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4*. Oncotarget, 2016. 7(4): p. 4624-31.
- 642 8. Moore, A.R., et al., *Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma.* Nat Genet, 2016. **48**(6): p. 675-80.
- Harbour, J.W., et al., *Frequent mutation of BAP1 in metastasizing uveal melanomas.* Science, 2010. 330(6009): p. 1410-3.
- 64610.Harbour, J.W., et al., Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal647melanoma. Nat Genet, 2013. 45(2): p. 133-5.
- 64811.Martin, M., et al., Exome sequencing identifies recurrent somatic mutations in EIF1AX and649SF3B1 in uveal melanoma with disomy 3. Nat Genet, 2013. 45(8): p. 933-6.
- 65012.Robertson, A.G., et al., Integrative Analysis Identifies Four Molecular and Clinical Subsets in
Uveal Melanoma. Cancer Cell, 2017. **32**(2): p. 204-220 e15.
- 452 13. Yavuzyigitoglu, S., et al., Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass
 453 Associated with Late-Onset Metastases. Ophthalmology, 2016. 123(5): p. 1118-28.
- 65414.Onken, M.D., et al., Gene expression profiling in uveal melanoma reveals two molecular655classes and predicts metastatic death. Cancer Res, 2004. 64(20): p. 7205-9.
- Field, M.G., et al., *Punctuated evolution of canonical genomic aberrations in uveal melanoma.*Nat Commun, 2018. 9(1): p. 116.
- 658 16. Shain, A.H., et al., *The genetic evolution of metastatic uveal melanoma.* Nat Genet, 2019.
 659 51(7): p. 1123-1130.
- Rodrigues, M., et al., *Evolutionary Routes in Metastatic Uveal Melanomas Depend on MBD4 Alterations.* Clin Cancer Res, 2019. 25(18): p. 5513-5524.
- 66218.Caravagna, G., et al., Subclonal reconstruction of tumors by using machine learning and663population genetics. Nat Genet, 2020. 52(9): p. 898-907.
- 66419.Durante, M.A., et al., Single-cell analysis reveals new evolutionary complexity in uveal665melanoma. Nat Commun, 2020. **11**(1): p. 496.
- 66620.Christodoulou, E., et al., Loss of Wild-Type CDKN2A Is an Early Event in the Development of667Melanoma in FAMMM Syndrome. J Invest Dermatol, 2020. 140(11): p. 2298-2301 e3.
- 66821.Nell, R.J., et al., Involvement of mutant and wild-type CYSLTR2 in the development and
progression of uveal nevi and melanoma. BMC Cancer, 2021. 21(1): p. 164.
- van Eijk, R., et al., Assessment of a fully automated high-throughput DNA extraction method
 from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation
 analysis. Exp Mol Pathol, 2013. 94(1): p. 121-5.
- 873 23. Nell, R.J., et al., Identification of clinically-relevant genetic alterations in uveal melanoma using RNA sequencing. 2023.
- Versluis, M., et al., *Digital PCR validates 8q dosage as prognostic tool in uveal melanoma.*PLoS One, 2015. **10**(3): p. e0116371.
- 67725.de Lange, M.J., et al., Heterogeneity revealed by integrated genomic analysis uncovers a678molecular switch in malignant uveal melanoma. Oncotarget, 2015. 6(35): p. 37824-35.
- Zoutman, W.H., R.J. Nell, and P.A. van der Velden, Usage of Droplet Digital PCR (ddPCR)
 Assays for T Cell Quantification in Cancer. Methods Mol Biol, 2019. 1884: p. 1-14.
- Nell, R.J., et al., Allele-specific digital PCR enhances precision and sensitivity in the detection
 and quantification of copy number alterations in heterogeneous DNA samples: an in silico and
 in vitro validation study. medRxiv, 2023: p. 2023.10.31.23297362.
- 68428.Dube, S., J. Qin, and R. Ramakrishnan, Mathematical analysis of copy number variation in a685DNA sample using digital PCR on a nanofluidic device. PLoS One, 2008. 3(8): p. e2876.

686 687	29.	Smit, K.N., et al., Combined mutation and copy-number variation detection by targeted next-
600	20	yen Facon TH, et al. Dragnactic percentary in uvent melanomy and their eccepticity with
689	30.	BAP1 expression. Br J Ophthalmol, 2014. 98 (12): p. 1738-43.
690	31.	Johnson, C.P., et al., Systematic genomic and translational efficiency studies of uveal
691		<i>melanoma</i> , PLoS One, 2017, 12 (6); p. e0178189.
692	32.	Johansson, P.A., et al., Whole genome landscapes of uveal melanoma show an ultraviolet
693	•=-	radiation signature in iris tumours Nat Commun 2020 11 (1): p 2408
694	33	Bidshahri R et al. Quantitative Detection and Resolution of BRAE V600 Status in Colorectal
605	55.	Cancer Using Dronlet Digital PCP and a Novel Wild-Type Negative Assay I Mol Diggn 2016
606		19(2) = 100.204
607	24	10(2). p. 130-204. Alasfadi S. at al. Canaar associated SE2P1 mutations affect alternative anliging by
600	34.	Alsaladi, S., et al., Cancer-associated SF3BT mutations affect alternative splicing by
090	05	promoting alternative branchpoint usage. Nat Commun, 2016. 7. p. 10615.
099	35.	Karisson, J., et al., <i>Molecular profiling of driver events in metastatic uveal melanoma.</i> Nat
700		Commun, 2020. 11 (1): p. 1894.
701	36.	Durinck, S., et al., Temporal dissection of tumorigenesis in primary cancers. Cancer Discov,
702		2011. 1 (2): p. 137-43.
703	37.	Nik-Zainal, S., et al., <i>The life history of 21 breast cancers</i> . Cell, 2012. 149 (5): p. 994-1007.
704	38.	Mitchell, T.J., et al., Timing the Landmark Events in the Evolution of Clear Cell Renal Cell
705		Cancer: TRACERx Renal. Cell, 2018. 173(3): p. 611-623 e17.
706	39.	Gerstung, M., et al., The evolutionary history of 2,658 cancers. Nature, 2020. 578(7793): p.
707		122-128.
708	40.	Martincorena, I. and P.J. Campbell, Somatic mutation in cancer and normal cells. Science,
709		2015. 349 (6255): p. 1483-9.
710	41.	Jolly, C. and P. Van Loo, <i>Timing somatic events in the evolution of cancer.</i> Genome Biol,
711		2018. 19 (1): p. 95.
712	42.	Gerlinger, M., et al., Intratumor heterogeneity and branched evolution revealed by multiregion
713		sequencing, N Engl J Med. 2012. 366(10); p. 883-892.
714	43.	Shain, A.H., et al., The Genetic Evolution of Melanoma from Precursor Lesions, N Engl J
715		Med. 2015. 373 (20): p. 1926-36.
716	44	Jamal-Haniani M et al. Tracking the Evolution of Non-Small-Cell Lung Cancer N Engl J
717		Med 2017 376 (22): p 2109-2121
718	45	Shain A H et al. Genomic and Transcriptomic Analysis Reveals Incremental Disruption of
719	10.	Key Signaling Pathways during Melanoma Evolution Cancer Cell 2018 34 (1): p 45-55 e4
720	46	Vader M I C, et al. GNAO and GNA11 mutations and downstream VAP activation in
721	40.	choroidal nevi Br I Cancer 2017 117 (6): p. 881-887
722	17	Durante MA et al. Cenomic evolution of uveal melanoma arising in ocular melanocytosis
723	47.	Cold Spring Harb Mol Case Stud. 2010. 5(4)
720	10	Silva Rodriguaz P. et al. CNAO and CNA11 Canas: A Comprehensive Paview on
725	40.	Oneogeneois Brognoois and Therapoutic Opportunities in Lived Melanema Cappars (Pasel)
720		Oncogenesis, Froghosis and Therapeulic Opportunities in Ovea Melanoma. Cancers (Daser),
720	40	2022. 14(13). Most W. st al. The betergraphic distribution of managemy 2 in usual malanemes:
720	49.	implications for programming the forest of the provide service biopoint. Arch Dethol Loh
120		Implications for prognostication based on fine-needle aspiration biopsies. Arch Pathol Lab
729	50	Med, 2007. 131(1): p. 91-6.
730	50.	Mensink, H.W., et al., Chromosome 3 intratumor heterogeneity in uveal melanoma. Invest
731		Ophthalmol Vis Sci, 2009. 50 (2): p. 500-4.
732	51.	Vichitvejpaisal, P., et al., Genetic Analysis of Uveal Melanoma in 658 Patients Using the
733		Cancer Genome Atlas Classification of Uveal Melanoma as A, B, C, and D. Ophthalmology,
734		2019. 126 (10): p. 1445-1453.
735	52.	Thornton, S., et al., <i>Targeted Next-Generation Sequencing of 117 Routine Clinical Samples</i>
736		Provides Further Insights into the Molecular Landscape of Uveal Melanoma. Cancers (Basel),
737		2020. 12 (4).
738	53.	Shields, C.L., et al., Ten-year outcomes of uveal melanoma based on The Cancer Genome
739		Atlas (TCGA) classification in 1001 cases. Indian J Ophthalmol, 2021. 69(7): p. 1839-1845.
740	54.	Jager, M.J., N.J. Brouwer, and B. Esmaeli, The Cancer Genome Atlas Project: An Integrated
741		Molecular View of Uveal Melanoma. Ophthalmology, 2018. 125(8): p. 1139-1142.
742	55.	Beasley, A., et al., Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA
743		<i>in Uveal Melanoma.</i> JCO Precis Oncol, 2018. 2 .

744 56. Carvajal, R.D., et al., Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat Med, 2022. 28(11): p. 2364-745 746 2373.